Keyphrases
Childbearing
100%
Mood Disorders
100%
Pharmacogenomics
100%
Perinatal Mental Health
100%
Tertiary Care
100%
Aged Persons
100%
Mental Hospital
100%
Metabolizer Status
100%
Cytochrome P450 2D6 (CYP2D6)
66%
Antidepressant Treatment
66%
Clinical Pharmacogenetics Implementation Consortium
66%
During Pregnancy
33%
African American
33%
Major Depressive Disorder
33%
Antidepressants
33%
Poor Response
33%
Severity Assessment
33%
Adverse Effects
33%
Drug-metabolizing Enzymes
33%
Bipolar Disorder
33%
DNA Samples
33%
Psychiatric Diagnosis
33%
Reproductive Outcome
33%
Enzyme Gene
33%
Diagnostic Assessment
33%
Sex at Birth
33%
Multiple Drugs
33%
Population Data
33%
Drug Trials
33%
Single nucleotide Variant
33%
Treatment Seeking
33%
Seeking Treatment
33%
Medication Side Effects
33%
Treatment History
33%
Cytochrome P450 1A2 (CYP1A2)
33%
CYP2C19
33%
Medication Response
33%
Psychiatric Severity
33%
Population Frequency
33%
Frequency Database
33%
Extensive Metabolizer
33%
Pharmacogenetic Variants
33%
Pharmacogenetic Testing
33%
Cytochrome P450 3A5
33%
Medicine and Dentistry
Side Effect
100%
Mental Health
100%
Tertiary Care
100%
Pharmacogenomics
100%
Mood Disorder
100%
Antidepressant
100%
Pharmacogenetics
66%
CYP2B6
66%
Single Nucleotide Polymorphism
33%
Major Depressive Episode
33%
Population Research
33%
Drug Screening
33%
Pharmacogenetic Testing
33%
CYP1A2
33%
Cytochrome P450 3A5
33%
Drug Metabolizing Enzyme
33%
Pharmacogenetic Variant
33%
Adverse Effect
33%
Bipolar Disorder
33%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacogenomics
100%
Pharmacogenetics
100%
Side Effect
100%
Antidepressant
100%
Mood Disorder
100%
CYP2B6
66%
Population Study
33%
Drug Screening
33%
Drug Metabolizing Enzyme
33%
Major Depression
33%
CYP1A2
33%
Cytochrome P450 3A5
33%
Bipolar Disorder
33%
Biochemistry, Genetics and Molecular Biology
Pharmacogenomics
100%
Mental Health
100%
Pharmacogenetics
100%
Single-Nucleotide Polymorphism
50%
Enzyme
50%
Pharmacogenetic Testing
50%
Population Research
50%
Drug Screening
50%
Pharmacogenetic Variant
50%
CYP1A2
50%
CYP2B6
50%
Neuroscience
Antidepressant
100%
Mood Disorder
100%
CYP2B6
66%
Major Depressive Disorder
33%
Bipolar Disorder
33%
Adverse Effect
33%
Drug Metabolizing Enzyme
33%
Cytochrome P450 1A2
33%
Cytochrome P450 3A5
33%
Pharmacogenetic Variant
33%
Single-Nucleotide Polymorphism
33%